Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cero Therapeutics Holdings Inc (CERO)

Cero Therapeutics Holdings Inc (CERO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 834
  • Shares Outstanding, K 20,803
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,300 K
  • EBIT $ -16 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -102.61
  • Most Recent Earnings $-9.10 on 11/19/25
  • Next Earnings Date 02/18/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0366 +9.56%
on 01/15/26
0.1041 -61.48%
on 12/19/25
-0.0450 (-52.88%)
since 12/16/25
3-Month
0.0366 +9.56%
on 01/15/26
2.5800 -98.45%
on 10/21/25
-2.3299 (-98.31%)
since 10/16/25
52-Week
0.0366 +9.56%
on 01/15/26
63.6000 -99.94%
on 01/30/25
-49.7599 (-99.92%)
since 01/16/25

Most Recent Stories

More News
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings,...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE)...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Announces Trading on OTCQB Market

Company’s Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”),...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing...

CERO : 0.0401 (+0.25%)
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO)...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Announces Listing on OTC Markets

Company’s Shares Will Continue to Trade Under Ticker CERO on the OTC Markets SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC PINK: CERO)...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Trading of the Company’s shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Holdings (CERO) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on CERo Therapeutics Holdings yesterday. The company’s shares opened today at $2.87.Elevate Your Investing Strategy: Take advantage of TipRanks...

CERO : 0.0401 (+0.25%)
CERo Therapeutics Enters Securities Purchase Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

CERO : 0.0401 (+0.25%)

Business Summary

CERo Therapeutics Holdings Inc. is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The company's lead product candidate includes CER-1236. CERo Therapeutics Holdings Inc., formerly known as Phoenix Biotech Acquisition Corp.,...

See More

Key Turning Points

3rd Resistance Point 0.0517
2nd Resistance Point 0.0488
1st Resistance Point 0.0445
Last Price 0.0401
1st Support Level 0.0373
2nd Support Level 0.0344
3rd Support Level 0.0301

See More

52-Week High 63.6000
Fibonacci 61.8% 39.3188
Fibonacci 50% 31.8183
Fibonacci 38.2% 24.3178
Last Price 0.0401
52-Week Low 0.0366

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar